Welcome to our dedicated page for C4 Therapeutics news (Ticker: CCCC), a resource for investors and traders seeking the latest updates and insights on C4 Therapeutics stock.
C4 Therapeutics, Inc. (Nasdaq: CCCC) is a pioneering clinical-stage biopharmaceutical company focused on utilizing targeted protein degradation to create novel medicines that transform patient outcomes. The company's core technology, the TORPEDO® platform, enables the design and optimization of small-molecule medicines aimed at degrading disease-causing proteins through the ubiquitin/proteasome system. This innovative approach offers solutions to overcome drug resistance and target previously undruggable proteins.
C4 Therapeutics is actively advancing several proprietary oncology programs into clinical trials. Notable among these is CFT7455, also known as cemsidomide, an oral degrader targeting IKZF1/3 for treating relapsed/refractory multiple myeloma (R/R MM) and non-Hodgkin’s lymphomas (R/R NHL). Recent clinical data indicates that CFT7455 is well-tolerated and exhibits promising anti-myeloma activity, supporting its continued development.
Another key program, CFT1946, is an oral BiDAC™ degrader designed to target BRAF V600 mutations. This compound is being tested for its efficacy in treating solid tumors, including non-small cell lung cancer (NSCLC), colorectal cancer (CRC), and melanoma. Early clinical results are promising, showing that CFT1946 is active against BRAF V600E-driven disease and exhibits central nervous system (CNS) activity, a significant advantage over existing BRAF inhibitors.
In addition to its internal programs, C4 Therapeutics has established strategic partnerships with industry leaders such as Roche, Biogen, and Merck KGaA, Darmstadt, Germany. These collaborations aim to leverage the company's TORPEDO® platform to discover and develop new degraders targeting various oncogenic proteins. Notably, under an agreement with Merck KGaA, C4T will receive an upfront payment and significant milestone payments, underpinning the potential commercial success of their partnered programs.
Financially, C4 Therapeutics reported a total revenue of $20.8 million for 2023, with a net loss of $132.5 million. However, the company is well-capitalized, with cash, cash equivalents, and marketable securities amounting to $281.7 million as of December 31, 2023, ensuring sufficient funds to support its operations into 2027.
By continuously pushing the boundaries of targeted protein degradation science, C4 Therapeutics aims to revolutionize the treatment landscape for patients with challenging diseases, ultimately striving to deliver breakthrough therapies that significantly enhance patient care and outcomes.
C4 Therapeutics, Inc. (Nasdaq: CCCC) announced key milestones and financial results for 2020, reporting revenue of $33.2 million, an increase from $21.4 million in 2019. The net loss expanded to $66.3 million, while cash reserves increased to $372 million, projected to support operations through 2023. The FDA cleared the IND for lead candidate CFT7455, with a Phase 1/2 trial set to begin in 1H 2021. An IND for CFT8634 is planned for 2H 2021. The company expects to advance multiple programs by year-end 2022, bolstering its strategic position in hematologic malignancies.
C4 Therapeutics, Inc. (Nasdaq: CCCC) announced that a late-breaking abstract featuring preclinical data for its protein degrader CFT7455 has been selected for presentation at the AACR 2021 Annual Meeting, scheduled for April 10-15, 2021. CFT7455 targets IKZF1/3 to treat hematologic malignancies and has demonstrated potent tumor regression in IMiD-resistant multiple myeloma models. This signifies a key milestone for C4T in advancing innovative cancer treatments through targeted protein degradation, potentially overcoming limitations of traditional therapies.
C4 Therapeutics, Inc. (Nasdaq: CCCC), a biopharmaceutical company innovating small-molecule medicines that degrade disease-causing proteins, has announced participation in two investor conferences in March 2021. They will present at the Cowen 41st Annual Health Care Conference on March 3 at 11:40 a.m. ET and the Guggenheim Targeted Protein Degradation Day on March 16 at 10:30 a.m. ET. Webcasts can be accessed on their website and will be available for two weeks post-event. C4T focuses on targeted protein degradation to treat cancer, neurodegenerative diseases, and more.
C4 Therapeutics (Nasdaq: CCCC) announced its participation in the BMO BioPharma Spotlight Series on February 18, 2021, at 10:30 a.m. ET. The panel discussion, titled “Ligating” Competitors for Collaboration in the Protein Degradation Space, will focus on next-generation technologies in protein degradation. A recording will be available for replay four hours post-event on the company’s website, archived for at least two weeks. C4T specializes in small-molecule medicines targeting disease-causing proteins, offering improved treatment options for cancer and neurodegenerative diseases.
C4 Therapeutics (Nasdaq: CCCC) announced FDA clearance of its IND application for CFT7455, an innovative oral MonoDAC targeting IKZF1/3, aimed at treating hematologic malignancies like multiple myeloma and non-Hodgkin lymphomas. This milestone allows the company to commence a Phase 1/2 clinical trial in the first half of 2021, following a positive 30-day safety review. The trial will evaluate CFT7455's safety, tolerability, and efficacy as a single agent and in combination therapies.
C4 Therapeutics, a biopharmaceutical company, announced its participation in the 39th Annual J.P. Morgan Healthcare Conference on January 14, 2021, at 2:50 p.m. ET. This event will showcase C4T's pioneering approach to developing small-molecule medicines that target and degrade disease-causing proteins. A live webcast of the presentation will be available in the Investors section of their website, with a replay accessible for two weeks post-event. C4T focuses on cancer and neurodegenerative disease treatments, emphasizing advantages like higher potency and reduced side effects.
C4 Therapeutics (Nasdaq: CCCC) has submitted an Investigational New Drug (IND) application for its lead candidate CFT7455, aimed at treating hematologic malignancies, with FDA review underway. A Phase 1/2 trial is anticipated to begin in the first half of 2021. Additionally, C4T plans to submit an IND for CFT8634 in the second half of 2021 and advance BRAF and RET programs into IND-enabling studies later this year. The company expects its current cash reserves of approximately $370 million to support operations through the end of 2023.
C4 Therapeutics, Inc. (Nasdaq: CCCC) has been added to the Russell 2000® and Russell 3000® Indexes, effective December 21, 2020. This inclusion follows their IPO just two months earlier and aims to enhance the company's visibility to investors. The Russell 2000® Index tracks small-cap stocks and serves as a benchmark for investment strategies, with around $9 trillion in assets connected to it. C4 Therapeutics focuses on developing small-molecule drugs to degrade disease-causing proteins, targeting cancer and neurodegenerative diseases.
C4 Therapeutics (Nasdaq: CCCC), a biopharmaceutical pioneer in targeted protein degradation, will present at the Evercore ISI 3rd Annual HealthCONx on December 3, 2020, at 8:25 a.m. ET.
Investors can access a live webcast of the presentation on the company’s website, with a replay available for two weeks post-event. C4T focuses on therapeutics that selectively destroy disease-causing proteins, offering potential advantages over traditional treatments, particularly in cancer and neurodegenerative diseases.
C4 Therapeutics (Nasdaq: CCCC), a biopharmaceutical innovator, will present at the Jefferies Virtual London Healthcare Conference on November 19, 2020, at 8:30 a.m. ET. C4T specializes in a unique class of small-molecule drugs aimed at selectively degrading disease-causing proteins, targeting conditions like cancer and neurodegenerative diseases. A live webcast of the presentation will be available on their website, with a replay archived for two weeks. This targeted protein degradation approach offers potential advantages over traditional therapies, including reduced drug resistance and fewer side effects.
FAQ
What is the current stock price of C4 Therapeutics (CCCC)?
What is the market cap of C4 Therapeutics (CCCC)?
What is the core technology of C4 Therapeutics?
What are the main focus areas of C4 Therapeutics’ current projects?
Who are some of C4 Therapeutics’ strategic partners?
What were C4 Therapeutics’ financial results for 2023?
What is CFT7455, also known as cemsidomide?
What is unique about CFT1946?
How does C4 Therapeutics’ technology address drug resistance?
What recent partnerships has C4 Therapeutics announced?
What are the cash and financial projections for C4 Therapeutics?
Where can I find more information about C4 Therapeutics' clinical trials?
